

Abemaciclib

Section

Targeted therapies

Indications

Therapeutic equivalent to **palbociclib** pour

Other specified malignant neoplasms of breast

Abiraterone

Section

Hormones and antihormones

Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

Adalimumab

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL;

10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Axial spondyloarthritis

Crohn disease site

Rheumatoid arthritis

Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to **erlotinib** pour

Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section

Targeted therapies

Oral > Solid: 10 mg capsule

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section

Supportive medicines

Parenteral > General injections > IV: 500 mg (as sodium) powder for injection

Oral > Solid: 100 mg; 300 mg

Indications

Tumour lysis syndrome

Anastrozole

Section

Hormones and antihormones

Oral > Solid: 1 mg tablet

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Arsenic trioxide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section

Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Atezolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab pour

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab pour

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

Axicabtagene ciloleucel

Section

Antineoplastics and supportive medicines

Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

Diffuse large B-cell lymphomas

Axitinib

Section

Targeted therapies

Oral > Solid > tablet: 1 mg; 3 mg; 5 mg

Indications

Renal cell carcinoma of kidney, except renal pelvis

Azacitidine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Myeloid leukaemia

Azathioprine

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 10 mg per mL

Oral > Solid > tablet: 25 mg; 50 mg (scored)

Oral > Solid > tablet: 50 mg (scored)

Indications

Failure or rejection of transplanted organs or tissues

Relapsing-remitting multiple sclerosis

Bendamustine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Bevacizumab

Section

Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

Hepatocellular carcinoma of liver

Bicalutamide

Section

Hormones and antihormones

Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib pour

Other specified melanoma of skin

Bleomycin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Blinatumomab

Section

Immunomodulators

Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial

Indications

B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Bortezomib

Section

Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

Calcium folinate (leucovorin calcium)

Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasm metastasis in large intestine

Capecitabine

Section

Cytotoxic medicines

Oral > Solid > tablet: 150 mg; 500 mg

Indications

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified gliomas of brain

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of cervix uteri

Cemiplimab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to pembrolizumab pour

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab pour

Adenocarcinoma of stomach

Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab pour

Axial spondyloarthritis

Therapeutic equivalent to adalimumab pour

Crohn disease site

Therapeutic equivalent to adalimumab pour

Rheumatoid arthritis

Chlorambucil

Section

Cytotoxic medicines

Oral > Solid: 2 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ciclosporin

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection

Oral > Liquid: 100 mg per mL

Oral > Solid > capsule: 25 mg

Indications

Failure or rejection of transplanted organs or tissues

Cisplatin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of cervix uteri

Cladribine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

Langerhans cell histiocytosis

Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib pour

Other specified melanoma of skin

Crizotinib

Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

Cyclophosphamide

Section

Cytotoxic medicines

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg; 50 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Malignant neoplasms of breast

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Plasma cell myeloma

Other specified gliomas of brain

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Cytarabine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Burkitt lymphoma including Burkitt leukaemia

Dabrafenib

Section

Targeted therapies

Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

Dacarbazine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Dactinomycin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Daratumumab

Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

Plasma cell myeloma

Darbepoetin alfa

Section

Supportive medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Drug-induced aplastic anaemia

Dasatinib

Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

Daunorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Dexamethasone

Section

Hormones and antihormones

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphosphate salt)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 4 mg (as dexamethasone base)

Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

Indications

Anaplastic large cell lymphoma, ALK-negative

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-positive

Docetaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

Dostarlimab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of corpus uteri

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Malignant neoplasms of breast

Hodgkin lymphoma

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Other specified malignant neoplasms of breast

Anaplastic large cell lymphoma, ALK-positive

Ewing sarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

Doxorubicin (as pegylated liposomal)

Section

Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Kaposi sarcoma of unspecified primary site

Durvalumab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Hepatocellular carcinoma of liver

Malignant neoplasms of biliary tract, distal bile duct

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of proximal biliary tract, cystic duct

Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib pour

Other specified melanoma of skin

Enzalutamide

Section

Hormones and antihormones

Oral > Solid: 40 mg

Indications

Therapeutic equivalent to abiraterone pour

Malignant neoplasms of prostate

Malignant neoplasms of prostate

Epoetin alfa

Section

Supportive medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Drug-induced aplastic anaemia

Epoetin beta

Section

Supportive medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Drug-induced aplastic anaemia

Erlotinib

Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Erythropoiesis-stimulating agents

Section

Supportive medicines

Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

Drug-induced aplastic anaemia

Etanercept

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) pour

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) pour

Crohn disease site

Therapeutic equivalent to [adalimumab](#) pour

Rheumatoid arthritis

Etoposide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule

Oral > Solid: 100 mg capsule

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)

Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Ewing sarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Germ cell tumour of testis

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Hodgkin lymphoma

Retinoblastoma

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Burkitt lymphoma including Burkitt leukaemia

Everolimus

Section

Targeted therapies

Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg

Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

Indications

Other specified gliomas of brain

Filgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropaenia

Fingolimod

Section

Immunomodulators for non-malignant disease
Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

Fludarabine

Section

Cytotoxic medicines
Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section

Cytotoxic medicines
Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per mL in vial

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of nasopharynx

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of rectum

Malignant neoplasms of colon

Flutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide pour

Malignant neoplasms of prostate

Fulvestrant

Section

Hormones and antihormones
Parenteral > General injections > IV: 250 mg per 5 mL

Indications

Malignant neoplasms of breast

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib pour

Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab pour

Axial spondyloarthritis

Therapeutic equivalent to adalimumab pour

Crohn disease site

Therapeutic equivalent to adalimumab pour

Rheumatoid arthritis

Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of prostate

Hydrocortisone

Section

Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Hydroxycarbamide (hydroxyurea)

Section

Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

Ibrutinib

Section

Targeted therapies

Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ifosfamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Burkitt lymphoma including Burkitt leukaemia

Imatinib

Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) pour

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) pour

Crohn disease site

Therapeutic equivalent to [adalimumab](#) pour

Rheumatoid arthritis

Ipilimumab

Section

Immunomodulators

Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Melanoma of skin

Irinotecan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Lenvatinib

Section

Targeted therapies

Oral > Solid > capsule: 4 mg; 10 mg

Indications

Renal cell carcinoma of kidney, except renal pelvis

Leuprorelin

Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Lisocabtagene maraleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to axicabtagene ciloleucel pour

Diffuse large B-cell lymphomas

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Mercaptopurine

Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Mesna

Section

Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule

Oral > Solid > tablet: 400 mg; 600 mg

Oral > Other: 600 mg

Oral > Solid > tablet: 400 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of the ovary

Osteosarcoma of bone and articular cartilage of other specified sites

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Germ cell tumour of testis

Methotrexate

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Oral > Solid: 2.5 mg (as sodium salt)

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Crohn disease site

Psoriatic arthritis

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Methylprednisolone

Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection

Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Nilotinib

Section

Targeted therapies

Oral > Solid > capsule: 150 mg; 200 mg

Indications

Chronic myeloid leukaemia, not elsewhere classified

Nilutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide pour

Malignant neoplasms of prostate

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

Therapeutic equivalent to pembrolizumab pour

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

Osimertinib

Section

Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Oxaliplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Paclitaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

Palbociclib

Section

Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

Panitumumab

Section

Targeted therapies

Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial

Indications

Other specified malignant neoplasms of large intestine

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pembrolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

Indications

Melanoma of skin

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of large intestine

Other specified malignant neoplasms of bronchus or lung

Adenocarcinoma of stomach

Squamous cell carcinoma of hypopharynx and variants

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Carcinoma of breast, specialised type

Squamous cell carcinoma of nasopharynx

Squamous cell carcinoma of oesophagus

Malignant neoplasms of oesophagogastric junction

Therapeutic equivalent to nivolumab pour

Melanoma of skin

Pertuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

Carcinoma of breast, specialised type

Prednisolone

Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of prostate

Hodgkin lymphoma

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to prednisolone pour

Plasma cell myeloma

Therapeutic equivalent to prednisolone pour

Follicular lymphoma

Therapeutic equivalent to prednisolone pour

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone pour

Hodgkin lymphoma

Therapeutic equivalent to prednisolone pour

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone pour

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to prednisolone pour

Langerhans cell histiocytosis

Therapeutic equivalent to prednisolone pour

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone pour

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone pour

Diffuse large B-cell lymphoma, not otherwise specified

Procarbazine

Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Rasburicase

Section

Supportive medicines

Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

Indications

Tumour lysis syndrome

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Ribociclib

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) pour

Other specified malignant neoplasms of breast

Rituximab

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Tacrolimus

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 5 mg per mL in 1 mL vial

Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension

Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

Failure or rejection of transplanted organs or tissues

Tamoxifen

Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Temozolomide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

Ewing sarcoma of bone and articular cartilage of unspecified sites

Other specified gliomas of brain

Unspecified malignant neoplasms of ill-defined or unspecified sites

Neuroblastoma, NOS

Thalidomide

Section

Immunomodulators

Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tioguanine

Section

Cytotoxic medicines

Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Tisagenlecleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to axicabtagene ciloleucel pour

Diffuse large B-cell lymphomas

Tislelizumab

Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL

Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

Squamous cell carcinoma of oesophagus

Toripalimab

Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Squamous cell carcinoma of oesophagus

Trametinib

Section

Targeted therapies

Oral > Solid: 0.5 mg; 2 mg

Indications

Other specified melanoma of skin

Trastuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Trastuzumab emtansine

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Tremelimumab

Section

Immunomodulators

Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

Hepatocellular carcinoma of liver

Other specified malignant neoplasms of bronchus or lung

Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of prostate

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib pour

Other specified melanoma of skin

Vinblastine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis

Vincristine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Kaposi sarcoma of unspecified primary site

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Retinoblastoma

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

Vinorelbine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Oral > Solid > capsule: 20 mg; 30 mg; 80 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast

Rhabdomyosarcoma primary site

Zanubrutinib

Section

Targeted therapies

Oral > Solid: 80 mg

Oral > Solid > capsule: 80 mg

Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to ibrutinib pour

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zoledronic acid

Section

Supportive medicines

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Malignant neoplasm metastasis in bone or bone marrow